Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD Patients

Abstract

Background: When inhaling medication, it is essential that drug particles are delivered to all sites of lung inflammation, including the peripheral airways. The aim of this study was to assess the lung deposition and lung distribution of beclomethasone dipropionate (BDP)=formoterol (100=6 mg), both dissolved in hydrofluoroalkane (HFA) and delivered by pressurized metered dose inhaler (pMDI) in healthy subjects, asthmatic, and chronic obstructive pulmonary disease (COPD) patients, to investigate how the in vitro characteristics of the formulation translate into the in vivo performance in diseases with different airway obstruction.

Control of asthma in adults treated with beclomethasone and formoterol in extrafine particle formulation in a real-life setting in Poland: the CASPER noninterventional, observational trial

“…The deposition of a beclomethasone and formoterol (BDP/F) combination in a pressurized metered--dose inhaler with Modulite HFA (BDP/F-pMDI HFA) in the lung is 34% of the nominal dose in healthy volunteers; 31%, in patients with asthma; and 33%, in patients with chronic obstructive pulmonary disease. [9][10][11][12] This is an improvement in drug accessibility, resulting in a better delivery of the dose when compared with the low-percentage deposition of CFC inhalers, and even compared with more modern powder inhalers with deposition rates ranging from 17% to 28%. 13 The mass median aerodynamic diameter, a measure of aerosol particle size (µm), is from 1.4 to 1.5 µm for the pMDI containing HFA-134a propellant, and this also ensures drug deposition in the small airways.…”

Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma

“…Deposition of inhaled corticosteroids administered via pMDIs with extra-fine particle formulations have demonstrated improved lung deposition compared with conventional pMDIs [42][43][44]. However, randomized controlled studies have, as yet, failed to demonstrate any significant differences in clinical effects compared with equivalent doses of conventional inhaled corticosteroid pMDIs [25][26][27][28].…”

Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD

“…It is also important that both components are distributed throughout the lung, including the peripheral airways, which in turn increases the potential for synergistic interaction [31].…”